TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.
about
Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell populationTyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemia.Alkylator-Induced and Patient-Derived Xenograft Mouse Models of Therapy-Related Myeloid Neoplasms Model Clinical Disease and Suggest the Presence of Multiple Cell Subpopulations with Leukemia Stem Cell ActivityGEP analysis validates high risk MDS and acute myeloid leukemia post MDS mice models and highlights novel dysregulated pathways.Higher expression levels of the HOXA9 gene, closely associated with MLL-PTD and EZH2 mutations, predict inferior outcome in acute myeloid leukemia.Regain control of p53: Targeting leukemia stem cells by isoform-specific HDAC inhibitionTIGAR cooperated with glycolysis to inhibit the apoptosis of leukemia cells and associated with poor prognosis in patients with cytogenetically normal acute myeloid leukemiaMutation profiling of 19 candidate genes in acute myeloid leukemia suggests significance of DNMT3A mutationsTherapy-related myeloid neoplasms: when genetics and environment collide.Allogeneic Hematopoietic Stem Cell Transplantation with Myeloablative Conditioning Is Associated with Favorable Outcomes in Mixed Phenotype Acute Leukemia.Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome.Acute erythroid leukemia with <20% bone marrow blasts is clinically and biologically similar to myelodysplastic syndrome with excess blasts.TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes.Histiocytic Sarcoma Associated with Coombs Negative Acute Hemolytic Anemia: A Rare Presentation.Sertad1 antagonizes iASPP function by hindering its entrance into nuclei to interact with P53 in leukemic cells.Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of TP53 mutational status.Characterization of TP53 mutations in low-grade myelodysplastic syndromes and myelodysplastic syndromes with a non-complex karyotype.Mixed phenotype acute leukemia contains heterogeneous genetic mutations by next-generation sequencing.Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications.Is there a pressing need for improving prognostication strategies in therapy-related myelodysplastic syndromes?More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia.
P2860
Q33731216-A9BC50D2-40C0-443F-B26A-593A6F2CA7F1Q33767026-FA01DEB5-9EA2-4DC0-9FB6-A7E192060CFBQ36080036-55E16194-0682-4B25-B3DA-BBBDEE671C7DQ36507980-11F09D9C-2503-4BC2-BD30-1BCBCCA02736Q36585150-2ECB2F67-4872-43C2-9C92-1F62A06DCD24Q36827373-AF7643E7-FD0B-444F-A681-6AFD77837DD8Q37440458-83E52DA6-0FB6-4033-97B2-D472F5305B21Q37688148-0DCBBD71-7A1B-485E-A985-78D6DF60D0F0Q38611096-C83B22DC-69D7-4697-A553-FE60A535B6D3Q38685482-FB58CF73-331F-448E-8EDD-DA0941B9FA5BQ38905610-447F8AB0-0644-4468-9A54-3C16BC5162E2Q39575152-54049EA4-D691-493F-981A-20B2B891F9F1Q40421122-072A716D-7518-412D-AC77-EBB427AFFF71Q41999207-A7AF5E44-8845-4B72-8593-7F934A1B8A1CQ47106228-C47EAB1B-2A1C-4056-A40B-251E16931434Q47158332-84CA0059-09A2-4D89-A5CA-EF0F775A33D4Q48323548-B035B850-4B94-40AC-87F8-E23FEAE9431AQ52371280-9F19E9B8-47EA-4D4C-AE2D-9D35B9D7C65EQ52668209-CF70FB08-1640-43D7-884A-EE2E3AA3D3CFQ52777531-EADEE096-7CED-4F96-A26E-97C4DC12EF3BQ53835607-4FF62C50-3EBF-4473-9B2C-2AFC98662E65Q55120146-28B14994-090F-4FC5-8479-7F12D2E8B7E1
P2860
TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
TP53 mutation characteristics ...... s similar to de novo diseases.
@ast
TP53 mutation characteristics ...... s similar to de novo diseases.
@en
type
label
TP53 mutation characteristics ...... s similar to de novo diseases.
@ast
TP53 mutation characteristics ...... s similar to de novo diseases.
@en
prefLabel
TP53 mutation characteristics ...... s similar to de novo diseases.
@ast
TP53 mutation characteristics ...... s similar to de novo diseases.
@en
P2093
P2860
P1476
TP53 mutation characteristics ...... s similar to de novo diseases.
@en
P2093
Chi Young Ok
Guilin Tang
Ken H Young
Keyur P Patel
L Jeffrey Medeiros
Maitrayee Goswami
Mark J Routbort
Rajesh Singh
Rajyalakshmi Luthra
P2860
P2888
P356
10.1186/S13045-015-0139-Z
P577
2015-05-08T00:00:00Z
P5875
P6179
1030448390